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Abstract 
Objective:  To develop and validate a self-reported health-related QUAlity of Life Assessment 
in Spina bifida for Children (QUALAS-C). 
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Methods:  We drafted a 27-question pilot instrument using a patient-centered comprehensive 
item generation/refinement process.  It was administered to a sample of children 8-12 years old 
with Spina Bifida (SB) recruited online via social media and in person at an outpatient SB clinic 
(January 2013-September 2014).  Healthy controls were recruited at routine pediatrician visits. 
Validation and final questions were determined based on clinical relevance, high loadings on 
factor analysis and domain psychometrics.  Children with SB also completed the validated 
generic Kidscreen-27 instrument. 
Results:  Median age of 150 participants was 9.6 years (60.7% male, 72.7% Caucasian), similar 
to 46 controls (p≥0.10).  There were 97 online and 53 clinic participants (89.0% and 84.2% of 
eligible, respectively).  Face and content validity of the 2-domain, 10-question QUALAS-C were 
established by patients, parents and experts.  Internal consistency and test-retest reliability was 
high for the Esteem & Independence and Bladder & Bowel domains (Cronbach’s alpha:  0.72-
0.76, ICC:  0.74-0.77).  Correlations between QUALAS-C domains were low (r=0.51), 
indicating that QUALAS-C can differentiate between two distinct health-related quality of life 
(HRQOL) components.  Correlations between QUALAS-C and Kidscreen-27 were also low 
(r≤0.44).  QUALAS-C scores were significantly lower in children with SB than without 
(p<0.0001). 
Conclusions:  QUALAS-C is a short, valid HRQOL tool for children with SB.  It will be useful 
in clinical and research settings. 
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Introduction 
Spina bifida (SB) is the most common congenital anomaly of the central nervous system, 
affecting 3.4 per 10,000 live births in the United States.
1
  Children surviving infancy face 
neurological, neurosurgical, orthopedic and urological challenges.  Unfortunately, studies on 
health-related quality of life (HRQOL) in children with SB tend to be small, single-institutional 
studies using limited, poorly-validated, or non-validated, instruments.
2-6
  Others report patient 
satisfaction, rather than HRQOL.
7,8
  Importantly, generic HRQOL instruments developed for 
healthy children
9,10
 may be unable to capture small, but clinically important, differences because 
they were not designed to measure the impact of SB on HRQOL.
11
  Moreover, no validated and 
comprehensive SB-specific HRQOL instrument exists which incorporates bladder and bowel 
domains.   
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SB-specific HRQOL is a component of quality of life that focuses on an individual’s 
perception of the impact of SB on their physical and psychosocial functioning.
11,12
  Assessing 
self-reported HRQOL is particularly important, as those with SB often report better HRQOL 
than perceived by their parents and caregivers.
13,14
  For this reason, instrument development 
requires input from individuals with SB, their parents and caregivers.
2,11
  An ideal, clinically 
relevant HRQOL instrument focuses on HRQOL, rather than physical function.  It should also 
possess excellent psychometric properties and be condition-specific, yet remain short and 
straightforward.
2,11
  Developing such an instrument is challenging in children, since a pediatric 
instrument must account for children’s changing cognitive capacity, reading skills and emotional 
development.
2
  Our goal was to develop and validate a clinically useful, self-reported, disease-
specific, health-related QUAlity of Life Assessment in Spina bifida for Children (QUALAS-C). 
 
Methods 
The study protocol followed the Federal Drug Administration recommendations for 
patient-reported outcome instrument development
15
 and was approved by the Internal Review 
Board (IRB 9470) and the Spina Bifida Association Professional Advisory Council. 
 
Eligibility and exclusion criteria 
Children (8 to 12 years old) with a history of myelomeniongocele or lipomeningocele 
requiring newborn spine surgery and living in the United States were recruited online via social 
media, or in person at an outpatient multidisciplinary SB clinic.  While age cutoffs are somewhat 
arbitrary, they were necessary to generate QUALAS-C and are supported by clinical experience.  
Similar ranges were successfully used for other pediatric instruments.
9,10
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The questionnaire was administered between January 2013 and September 2014.  Non-
eligibility criteria included:  diagnosis other than spina bifida (e.g. primary tethered cord, sacral 
agenesis), poor self-reported English proficiency (“a little bit,” “some,” rather than “well,” “very 
well” on a 4-point Likert scale), developmental delay interfering with comprehension of 
questions, or surgery in the last month.  In clinic, developmental delay was assessed by parents, 
health care providers and investigators, without routine psychological testing.  Children 
participating online were assessed for significant delay by their parents.  Eligible participants 
were excluded if they did not complete the questionnaire.  Eligibility and exclusion criteria 
remained unchanged throughout the study.  Healthy controls without SB were recruited from two 
local pediatric clinics during routine checkup visits.  
 
Phase 1.  Item generation 
We used a patient-centered, comprehensive item generation and refinement process 
(Figure 1).  Items were generated from transcripts of 10 semi-structured interviews with children 
with SB and their families (by KMS).  Items were also drafted based on a review of published 
instruments and the opinions of 21 national and international experts in SB care (see 
Acknowledgments).  The item generation process continued until reaching the saturation point, 
when no new items were generated. This comprehensive list of 130 items covered 11 
child/parent/expert-derived themes of cognition, independence, emotional impact, social 
interactions, educational, leisure activities, mobility, healthcare interactions, toileting, as well as 
urinary and fecal continence.  This list was reduced to 72 items by an expert panel, who 
eliminated redundant items, while maintaining the themes. 
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Phase 2. Development of pilot instrument 
The 72 items were rated on importance by 6 children with SB and 6 parents from our SB 
clinic.  Ratings were made on a 3-point Likert scale (“not important,” “somewhat important,” 
“very important”).  After review by a local SB expert panel (see Acknowledgements), 27 items 
with the highest rankings were selected to create a more manageable and representative pilot 
QUALAS-C.  This item reduction approach has been successfully used in the SB population.
4,5,16
  
Some items were reworded to ensure comprehension and clarity.  Rewording was based on 
feedback from the 12 individuals rating the questions and a Health Literacy Educator (see 
Acknowledgments).  Readability was assessed by the Flesch Kincaid Grade Level test.
17
 
The pilot QUALAS-C was self-administered.  Questions were close-ended and numbered 
to avoid omission.  Similar to other pediatric instruments, questions reflected the 4 weeks prior 
to answering the questions.
5,10,18
  Responses used a 5-point Likert scale (never, almost never, 
sometimes, almost always, always), an approach successfully used in other instruments.
4,5,9,10,18
  
Items focusing on similar themes were grouped together to simulate the final QUALAS-C 
instrument. 
 
Phase 3.  Further participant recruitment 
The pilot QUALAS-C and demographic questionnaire were administered anonymously 
to 150 children with SB and 46 controls in a cross-sectional survey (January 2013 to September 
2014).  Children with SB also completed the Kidscreen-27, a validated general HRQOL 
instrument.
9
  In order to open the study to children from a variety of social and health care 
setting, participants were recruited through local, national and international SB organizations via 
social media (see Acknowledgments) and at our outpatient multidisciplinary SB clinic.  Consent 
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was obtained online (computer-based) or in person (clinic-based).  Test-retest reliability was 
assessed by readministering the QUALAS-C two weeks later to participants recruited in clinic.  
A $5 incentive payment was provided. 
 
Phase 4.  Refinement of instrument and factor analysis 
After reviewing responses to the 27-item pilot QUALAS-C by a panel of local SB 
experts, one item was removed secondary to a high missing rate (>50% participants did not 
answer).  For adequate statistical power, a factor analysis on the remaining 26 items would 
require at least 130 participants with SB (26x5 participants/item).
19,20
   
We used factor analysis to statistically verify which of the child/parent/expert-derived 
items and themes work well in validated QUALAS-C domains.  Briefly, extracted factors were 
based on 4 criteria: 
21
  (1) examining standard scree plots of unrotated and varimax (orthogonal) 
rotated factor analyses,(2) extracting factor models with different numbers of factors and rotating 
them using 5 additional rotations (4 orthogonal, 1 oblique) to verify factor structure stability, (3) 
ensuring extracted factors had at least 3 variables with loadings 0.4 or greater, and (4) 
confirming statistical properties and clinical  plausibility/relevance of each resulting domain.  
Based on these criteria, the final QUALAS-C instrument consisted of 2 domains with 5 items 
each.  QUALAS-C is scored 0-100, where higher values signify higher HRQOL, and takes <5 
minutes to complete.   
 
Phase 5.  Validation 
We assessed several types of validity among participants with SB to determine if the 10-
question QUALAS-C measures what it was intended to measure.
22
  Face and content validity 
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were established through a review by patients, families and experts.  Construct validity was 
additionally assessed through factor analysis.  For each domain score, we calculated the mean, 
standard deviation (SD), median, range and the percentage of subjects scoring the minimum 
(floor) and maximum (ceiling).  Reliability, or reproducibility, was assessed by measuring 
internal consistency and test-retest reliability.
22
  Internal consistency refers to the degree of 
correlation between items in the instrument.  It was measured by Cronbach’s alpha (0.7-0.9 
signifying robust consistency without redundancy).
22
  Two-week test-retest reliability was 
assessed by Intraclass Correlation Coefficient (ICC), which accounts for the direction of change 
(≥0.7 indicating good reliability), using a SAS macro written by Lu and Shara.23   
Convergent and divergent validity evaluates conceptual independence or redundancy.  
Convergent validity evaluates the degree to which QUALAS-C scores converge with other 
instruments measuring similar outcomes.  On the other hand, divergent validity evaluates the 
degree to which QUALAS-C scores diverge from those measured by dissimilar instruments.  To 
assess this, we calculated Pearson correlation coefficients (r) among QUALAS-C domains and 
with Kidscreen-27 domains.  To quantify effect size, we used a previously established method of 
dividing the mean difference between children with SB and controls by the SD of the control 
population.
24,25
 
Several distribution-based approaches were used to determine the minimal clinically 
important difference that could be detected.  Estimated point differences were determined using 
(1) 0.5 SD,
26
 or (2) internal consistency or (3) test-retest reliability in the formula 
SD´ (1- reliability) .27  We selected the most conservative, largest point difference calculated 
by the three methods as the minimally important score difference for each domain.   
To further evaluate construct validity, domain scores between children with SB and 
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controls were compared using a t-test.  A critical p=0.05 was used.  All statistical analyses were 
performed using SAS software (v9.4, SAS Institute, Cary, NC). 
 
Results 
Phases 1 and 2.  Item generation and Development of pilot instrument 
The 27-item pilot instrument was developed in a multifaceted, patient-centered fashion 
(Figure 1).   Ten semi-structured interviews lasted a mean of 20 minutes.  
 
Phase 3. Further participant recruitment (Demographics) 
Of 104 clinic patients screened, 63 (60.6%) met eligibility criteria, and 53 (84.1%) were 
ultimately enrolled (Figure 2).  Of 110 online participants, 109 (99.1%) met eligibility criteria, 
and 97 (89.0%) were enrolled.  We observed no significant differences in gender and age 
between eligible children who were and were not enrolled.  Forty-six controls without SB were 
enrolled. 
 Median age of 150 participants was 9.6 years (60.7% male, 72.7% Caucasian), similar to 
controls (p≥0.10) (Table 1).  Half (57.3%) were community ambulators (walked with/without 
aids, using wheelchair for only long trips)
28
 and 63.3% had a ventriculoperitoneal shunt.  Most 
performed clean intermittent catheterizations (76.7%) and 59.3% reported daytime urinary dry 
intervals of at least 4h.  Participants lived in 34 states of the United States, encompassing 87% of 
the country’s population in 2011 (eTable 1).  
 
Phase 4.  Refinement of instrument and factor analysis 
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 After removal of one item due to a high missing rate, 26 items were analyzed with factor 
analysis.  A break in the slope of scree plots from two principal factor analyses, unrotated and 
varimax rotated, suggested the presence of two meaningful factors, followed by a decreasing 
slope of minor factors (eTable 2).  Similar findings were obtained on the other 5 rotations.  The 
first two extracted factors were retained to become QUALAS-C domains (Esteem and 
Independence, Bladder and Bowel) and accounted for 68.2% of the total variance. 
 
Phase 5. Validation 
A review by patients, families and experts established face and content validity of the 
final 10-question QUALAS-C.  The Flesch Kincaid Grade Level test indicated a third grade 
reading level.  Characteristics of the QUALAS-C domain scores were calculated among children 
with SB, without evidence of floor or ceiling effects (Table 2).  Each domain had acceptable 
internal consistency (Cronbach’s alpha: 0.72-0.76) and test-retest validity (ICC: 0.74-0.77).  The 
mean two-week test-retest changes were small for each domain (range: -1.0 to +1.1).  Missing 
data was acceptably low for each domain (Esteem and Independence: 0.0%, Bladder and Bowel: 
4.7%).  
Correlations between QUALAS-C domains were low (r=0.51), indicating that QUALAS-
C can differentiate between two distinct HRQOL components (eTable 3).  Correlations between 
QUALAS-C and Kidscreen-27 domains were also low (r≤0.44), indicating that these instruments 
assess different aspects of HRQOL.  Domain characteristics were similar for participants 
recruited online and in clinic.   
The minimally important difference was ≥10 for either domain (range of values: 9.7-
10.7). 
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QUALAS-C scores for controls were significantly higher than children with SB for both 
domains (p<0.0001), each with a large effect size (≥1.1) (eTable 4).  Similar to children with 
SB, missing data was low for each domain (Esteem and Independence: 0.0%, Bladder and 
Bowel: 0.0%).   
 
Comment 
 We present a short, novel, validated HRQOL instrument developed specifically for 
children with SB.  QUALAS-C is composed of items relevant to children with SB, their families 
and clinicians, including a comprehensive domain focusing on bladder and bowel dysfunction.  
We also report minimally important differences in HRQOL scores, which may help patients, 
clinicians and researchers to focus on differences that are statistically and clinically significant.  
Three previously published SB-specific HRQOL instruments in children have serious 
limitations.  Importantly, none have a patient-reported version for children younger than 13 years 
old.
4-6
  Furthermore, each instrument has 44 to 51 items, making them cumbersome and time-
consuming.  Since none of these instruments was designed using factor analysis, all remain 
suspect for item redundancy and appropriate domain groupings.  In addition, the Hydrocephalus 
Outcome Questionnaire was developed without input from individuals with SB.
5
  While children, 
families and SB experts overwhelmingly endorsed bladder/bowel care and incontinence as 
important aspects of HRQOL, only the Fecal Incontinence and Constipation QOL instrument 
contains items addressing bowel issues.
6
  Finally, it remains unclear what score difference, or 
change, may be clinically relevant when using existing instruments. 
Our primary goal was to create a clinically meaningful and useful instrument, rather than 
a research tool.  The low rate of missing data suggests that QUALAS-C is not difficult to 
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complete.  If only 4 of 5 responses are provided for a domain, we suggest using the mean of 
these items for a domain score.
29
  QUALAS-C domains can be used together or on their own.  
QUALAS-C was developed because current generic HRQOL instruments are insufficient 
for children with SB.  This is largely due to the fact that instruments developed for healthy 
children fail to capture aspects of HRQOL important to people living with SB.  As the 
fundamental concept of HRQOL may be different between individuals with and without SB, 
QUALAS-C scores of healthy controls likely hold no clinical relevance and were used only to 
calculate validation statistics.  QUALAS-C scores may be best compared longitudinally to the 
same person over time, or between children with SB.  Finally, QUALAS-C evaluates the specific 
impact of SB on HRQOL, rather than generic HRQOL or global quality of life. 
Our study has several limitations.  While we cannot verify how much assistance online 
participants received from their parents.  It should be noted that while QUALAS-C was often 
filled out with some parental help in clinic (i.e. reading questions), all questions were assessed 
from the child’s perspective.  It is unrealistic to insist that children with SB fill out a HRQOL 
instrument completely on their own, as few would be able to do so. 
Although we did not detect evidence of significant selection bias, as eligible participants 
who were and were not enrolled had similar demographics, study participants may have fewer 
developmental and functional limitations than the general SB population and non-participants.  
An external validation is needed. 
While we did not use anchor-based methods to calculate minimally important differences, 
distribution- and anchor-based methods have been shown to give comparable results.
30
  
QUALAS-C was validated only for children with SB.  Whether it can be used in other 
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populations remains to be seen.  Finally, being a validation study, we did not assess risk factors 
for lower HRQOL.  This will be the focus of future work. 
 
Conclusion 
QUALAS-C is a short, validated tool for evaluating HRQOL in children with SB.  It 
assesses important clinical domains, making it a useful instrument in both clinical and potential 
research settings. 
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Figure legends 
Figure 1.  Creation of the QUAlity of Life Assessment in Spina bifida in Children 
(QUALAS-C) 
Abbreviations:  SB: Spina Bifida. 
 
Figure 2. Enrollment of children into the study 
Children were enrolled at an outpatient multidisciplinary spina bifida as well as online 
via social media.  Enrollment commenced in January 2013 through September 2014 (20 
months).  Healthy controls without SB were recruited from two local pediatric clinics 
during routine checkup visits. 
 
 
Table 1.  Population characteristics. 
Patient Characteristics Participants (n=150) Controls (n=46) p-value 
Age, mean (SD), years 9.6 (1.4) 10.0 (1.2) 0.10 
Male gender, No. (%) 91 (60.7%) 25 (54.3%) 0.49 
Race       
Caucasian 109 (72.7%) 28 (60.8%) 0.14 
Hispanic 21 (14.0%) 3 (6.5%)  
African-American 6 (4.0%) 7 (15.2%)  
East Asian 7 (4.7%) 0 (0.0%)  
Nativea  1 (0.7%) 0 (0.0%)  
Multiethnic 5 (3.3%) 8 (17.4%)  
Unknown 1 (0.7%) 0 (0.0%)  
Household arrangements, No. (%)      
Parent(s) 145 (96.7%) 44 (95.7%) 0.67 
Other    
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   Grandparent(s) only 4 (2.7%) 0 (0.0%)  
   Uncle/aunt only 0 (0.0%) 2 (4.4%)  
   Unknown 1 (0.7%) 0 (0.0%)  
Mobility, No. (%)      
Community ambulator 86 (57.3%) 46 (100.0%) <0.001  
Not a community ambulator 59 (39.3%) 0 (0.0%)  
Unknown 5 (3.3%) 0 (0.0%)   
Ventriculoperitoneal shunt, No. 
(%)      
Yes 95 (63.3%) 0 (0.0%)   
No 45 (30.0%) 46 (100.0%) <0.001 
Unknown 10 (6.7%) 0 (0.0%)  
Clean intermittent 
catheterizations, No. (%)      
Yes 115 (76.7%) 0 (0.0%) <0.001 
No 32 (21.3%) 46 (100.0%)  
Unknown 3 (2.0%) 0 (0.0%)  
Social urinary continence (≥4h dry 
period), No. (%)      
Yes  89 (59.3%) 45 (97.8%) <0.001 
No 59 (39.3%) 1 (2.2%)  
Unknown 2 (1.3%) 0 (0.0%)  
Catheterizable channel, No. (%)      
Yes  52 (34.7%) 46 (100.0%) <0.001 
No 88 (58.7%) 0 (0.0%)  
Unknown 10   (6.7%) 0 (0.0%)  
Bladder augmentation, No. (%)      
Yes  39 (26.0%) 46 (100.0%) <0.001 
No 98 (65.3%) 0 (0.0%)  
Unknown 13   (8.7%) 0 (0.0%)  
Totals may not add up to 100% due to rounding.   
Abbreviations:  SD, standard deviation.   
aNative American, Alaska Native, Inuit, Aboriginal, Maori, etc.   
 
Table 2.  Domain characteristics of the self-reported QUALAS-C 
Domain N 
% 
missin
g 
Mea
n 
(SD) 
Median 
(Range
) 
% 
Scoring 
Minimu
m 
% 
Scoring 
Maximu
m 
Cronbach’
s alpha 
Test-
retest 
reliabilit
y (ICC) 
Esteem and 
Independen
15
0 0.0 
71.6 
(19.3
72.5 
(10.0- 0.0 12.7 0.72 0.77 
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ce ) 100.0) 
Bladder and 
Bowel 
14
3 4.7 
70.7 
(21.0
) 
70.0 
(15.0-
100.0) 
0.0 14.0 0.76 0.74 
Abbreviations:  QUALAS-C: QUAlity of Life Assessment in Spina bifida for Children; SD: 
Standard Deviation; ICC: Intraclass Correlation Coefficient. 
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The goal of caring for a child with spina bifida should be to help them live as normal a life as 
possible.  In order to achieve this goal, we as providers may perform procedures that are 
medically necessary as well as those that help them to become more independent and “fit” better 
into everyday life.  Who decides what is “normal”?  The challenge of managing patients with a 
birth defect that results in varying degrees of physical limitations, bowel and bladder 
dysfunction, and neurologic issues becomes even more difficult as the child ages.  Along with 
the potential need of undergoing multiple surgeries, these individuals must work toward 
independence in the face of aging parents or caregivers, integrate themselves into school and 
work, strive for a sense of belonging into a society filled with discrimination and prejudice, and 
ultimately be provided adequate access to medical care as they transition into adulthood.  Despite 
advances in medical care, it is still quite difficult to compare outcomes across institutions as we 
have yet to standardize our approach to patients with spina bifida.  The current paper highlights 
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the importance of having a tool to truly measure health related quality of life in this patient 
population.  As stated, quality of life can be perceived very differently between guardian and 
patient yet, both reported outcomes are extremely important to us as caretakers to ensure that we 
are on the right path to counsel and prepare both guardian and child for their journey ahead.  
Despite the mentioned limitations and need for external validation, this construction of a self-
reported health related quality of life assessment tool is one more step to helping these children 
communicate how their lives are affected by spina bifida.  In return, we can use this information 
to help personalize our approach to each individual patient to help them achieve the best possible 
outcomes. 
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